Check-Cap (NASDAQ:CHEK) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

Check-Cap stock opened at $0.91 on Tuesday. Check-Cap has a fifty-two week low of $0.56 and a fifty-two week high of $3.45. The firm’s 50-day simple moving average is $0.94 and its 200 day simple moving average is $1.11. The stock has a market cap of $5.30 million, a PE ratio of -0.30 and a beta of 0.19.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.